Advanced search
Publication Cover
Journal of Market Access & Health Policy Volume 7, 2019 - Issue 1
Journal homepage
1,176
Views
0
CrossRef citations to date
0
Altmetric
Original Research Article

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses

Katia ThokagevistkHealth Economics and Outcomes Research, Creativ-Ceutical, Paris, France
,
Clément FrançoisHealth Economics and Outcomes Research, Creativ-Ceutical, Paris, France;Public Health Department- Research Unit, Aix-Marseille University, Marseille, FranceCorrespondence[email protected]
,
Mélanie BrignoneHealth Economics and Outcomes Research, Lundbeck SAS, Paris
&
Mondher ToumiHealth Economics and Outcomes Research, Creativ-Ceutical, Paris, France;Public Health Department- Research Unit, Aix-Marseille University, Marseille, France
Article: 1603538 | Received 03 Aug 2018, Accepted 29 Mar 2019, Published online: 15 Apr 2019

References

  • Llorca PM, Lançon C, Brignone M, et al. Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram. J Mark Access Health Policy. 2015 Sep 24;3. eCollection 2015. DOI:10.3402/jmahp.v3.26776.
  • Thokagevistk K, Khemiri A, Dorey J, et al. Evolution of tiotropium efficacy vs. placebo over time for the maintenance therapy of chronic obstructive pulmonary disease: from investigational product to active reference. Value Health. 2015 Nov;18(7):A495. Epub 2015 Oct 20. .
  • Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14:417_28.
  • European Medicines Agency. Brintellix. 2013 [cited 2013 Oct 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002717/WC500159447.pdf
  • Tansey MJ, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci. 1993 Jan;114(1):109–11.
  • Winner P, Landy S, Richardson M, et al. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Clin Ther. 2005 Nov;27(11):1785–1794.
  • Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633–658.
  • Migraine: Developing Drugs for Acute Treatment Guidance for Industry. (2018). Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm419465.pdf
  • Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. Wiley, Chichester, U.K.; 2000. xvii+317. ISBN 0-471-49066-0.
  • Thompson SG. Meta-analysis of clinical trials. In: Armitage P, Colton T, editors. Encyclopedia of Biostatistics. Chichester: Wiley; 1998. p. 2570–2579.
  • Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009 Oct;62(10):1006–1012. Epub 2009 Jul 23.
  • Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4;297(13):1443–1454.
  • Sheftell FD, Dahlof CG, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther. 2005;27(4):407–417.
  • Landy S, Savani N, Shackelford S, et al. Efficacy and tolerability of sumatriptan tablets administered during the mild-pain phase of menstrually associated migraine. Int J Clin Pract. 2004;58(10):913–919.
  • Winner P, Mannix LK, Putnam DG, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc. 2003;78(10):1214–1222.
  • Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the USA food and drug administration. Pharmacotherapy. 2004 Jun;24(6):743–749.
  • Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the USA Food and Drug Administration‘s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014 Apr;37(4):283–294.
  • Tuttle AH, Tohyama S, Ramsay T, et al. Increasing placebo responses over time in U.S. clinical trials of neuropathic pain. Pain. 2015 Dec;156(12):2616–2626.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.